Sanofi invests in French vaccine production facility

Modesto Morganelli
Ottobre 13, 2017

The new facility is being developed to support the firm's global vaccines business unit to expand supply of VaxigripTetra to around 70 countries in six continents.

Sanofi Pasteur head and Sanofi executive vice president David Loew said: "Influenza continues be a major public health problem around the world, causing serious complications, hospitalizations and deaths, mostly for certain high-risk individuals. As a global leader in flu vaccines, this expansion reinforces Sanofi Pasteur's ability to tackle this underestimated health challenge", David Loew, a Sanofi EVP and head of Sanofi Pasteur, said in a statement.

The site in Val de Reuil, about 100km northwest of Paris, manufactures a number of antigens for Sanofi-Pasteur's vaccine portfolio, including meningococcal meningitis, yellow fever, mumps, influenza, hepatitis B, poliomyelitis, rabies.

Sanofi did not respond to requests for more information from this publication at the time of going to press.

Added Philippe Luscan, Sanofi's EVP, Global Industrial Affairs: "Our investment underlines Sanofi's intent to strengthen our industrial capacities in France as a major center of influenza vaccines production for worldwide markets".

The expansion is planned to be completed by 2021, subject to relevant health authority approvals, and production of vaccines in this new facility is anticipated to begin in 2022.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE